{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:20:11Z","timestamp":1790612411578,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.dmpk.2024.101019","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T11:32:58Z","timestamp":1715254378000},"page":"101019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-1469","authenticated-orcid":false,"given":"Ryuta","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-6543","authenticated-orcid":false,"given":"Tomohisa","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2024.101019_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmpk.2024.101019_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmpk.2024.101019_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrd3439","article-title":"Phase II failures: 2008\u20132010","volume":"10","author":"Arrowsmith","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.dmpk.2024.101019_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101019_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/psp4.12049","article-title":"Good practices in model-informed drug discovery and development: practice, application, and documentation","volume":"5","author":"Marshall","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2024.101019_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1208\/s12248-019-0339-5","article-title":"Translational quantitative systems pharmacology in drug development: from current landscape to good practices","volume":"21","author":"Bai","year":"2019","journal-title":"AAPS J"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101019_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/psp4.12709","article-title":"Quantitative systems pharmacology: landscape analysis of regulatory submissions to the US Food and Drug Administration","volume":"10","author":"Bai","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101019_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/psp4.12282","article-title":"Preclinical QSP modeling in the pharmaceutical industry: an IQ consortium survey examining the current landscape","volume":"7","author":"Nijsen","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10928-022-09805-z","article-title":"Two heads are better than one: current landscape of integrating QSP and machine learning","volume":"49","author":"Zhang","year":"2022","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmpk.2024.101019_bib10","first-page":"1","article-title":"Current practices for QSP model assessment: an IQ consortium survey","author":"Chan","year":"2022","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101019_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1254\/fpj.153.124","article-title":"Estimation of mechanism-of-action of pharmaceutical compounds based on quantitative systems pharmacology","volume":"153","author":"Saito","year":"2019","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.dmpk.2024.101019_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4041827","article-title":"Estimation of the mechanism of adrenal action of endocrine-disrupting compounds using a computational model of adrenal steroidogenesis in NCI-H295R cell","volume":"2016","author":"Saito","year":"2016","journal-title":"J Toxicol"},{"key":"10.1016\/j.dmpk.2024.101019_bib13","first-page":"420","article-title":"Prediction of drug-induced liver injury using quantitative systems toxicology model DILIsym","volume":"54","author":"Saito","year":"2018","journal-title":"Farumasia"},{"issue":"8","key":"10.1016\/j.dmpk.2024.101019_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/bdd.2040","article-title":"Physiologically based pharmacokinetic-pharmacodynamic modeling to predict concentrations and actions of sodium-dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules","volume":"37","author":"Mori","year":"2016","journal-title":"Biopharm Drug Dispos"},{"issue":"8\u20139","key":"10.1016\/j.dmpk.2024.101019_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/bdd.2253","article-title":"Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics","volume":"41","author":"Mori-Anai","year":"2020","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101019_bib16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.mayocpiqo.2022.09.002","article-title":"Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus","volume":"6","author":"Wish","year":"2022","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101019_bib17","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.2c00402","article-title":"Discovery of apararenone (MT-3995) as a highly selective, potent, and novel nonsteroidal mineralocorticoid receptor antagonist","volume":"65","author":"Iijima","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmpk.2024.101019_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2013 new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.dmpk.2024.101019_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/dom.14601","article-title":"Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials","volume":"24","author":"Chaudhuri","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101019_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1210\/endrev\/bnz010","article-title":"The new biology of diabetic kidney disease\u2014mechanisms and therapeutic implications","volume":"41","author":"Lytvyn","year":"2020","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.dmpk.2024.101019_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"10","key":"10.1016\/j.dmpk.2024.101019_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.dmpk.2024.101019_bib24","first-page":"271","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside","volume":"vol. 243","author":"Kolkhof","year":"2017"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","article-title":"Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease","volume":"65","author":"Buglioni","year":"2015","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.dmpk.2024.101019_bib27","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1152\/ajpendo.00022.2023","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"Yao","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101019_bib29","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101019_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2169\/internalmedicine.46.6415","article-title":"Analysis of factors causing hyperkalemia","volume":"46","author":"Takaichi","year":"2007","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.dmpk.2024.101019_bib31","first-page":"R865","article-title":"Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models","volume":"259","author":"Guyton","year":"1990","journal-title":"Am J Physiol"},{"issue":"11","key":"10.1016\/j.dmpk.2024.101019_bib32","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s10439-005-5976-4","article-title":"Long-term mathematical model involving renal sympathetic nerve activity, arterial pressure, and sodium excretion","volume":"33","author":"Karaaslan","year":"2005","journal-title":"Ann Biomed Eng"},{"issue":"9","key":"10.1016\/j.dmpk.2024.101019_bib33","doi-asserted-by":"crossref","first-page":"R647","DOI":"10.1152\/ajpregu.00039.2013","article-title":"A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model","volume":"306","author":"Hallow","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2024.101019_bib34","first-page":"11","article-title":"Development of a quantitative systems pharmacology model for prediction of mineralocorticoid receptor antagonists-induced hyperkalemia (W-044)","volume":"44","author":"Nakada","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"10.1016\/j.dmpk.2024.101019_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJM198102123040701","article-title":"Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy","volume":"304","author":"Batlle","year":"1981","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"issue":"8252","key":"10.1016\/j.dmpk.2024.101019_bib37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(81)91392-1","article-title":"Low sodium\/high potassium diet for prevention of hypertension: probable mechanisms of action","volume":"2","author":"Skrabal","year":"1981","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dmpk.2024.101019_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.dmpk.2024.101019_bib39","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.dmpk.2024.101019_bib40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3949\/ccjm.84a.17056","article-title":"Diagnosis and treatment of hyperkalemia","volume":"84","author":"Palmer","year":"2017","journal-title":"Cleve Clin J Med"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101019_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.ajkd.2010.01.020","article-title":"A physiologic-based approach to the evaluation of a patient with hyperkalemia","volume":"56","author":"Palmer","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.dmpk.2024.101019_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/cpdd.855","article-title":"Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist apararenone in healthy volunteers","volume":"10","author":"Nakamura","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.dmpk.2024.101019_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436724000259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:17:30Z","timestamp":1756397850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436724000259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"alternative-id":["S1347436724000259"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101019","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trials","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2024.101019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101019"}}